Scientists from the HIV Prevention Trials Network recently found that long-acting cabotegravir (CAB LA) injections once every eight weeks was better than the daily tablet used for HIV prevention.
Scientists from the HIV Prevention Trials Network recently found that long-acting cabotegravir (CAB LA) injections once every eight weeks was better than the daily tablet used for HIV prevention.